Product Overview
Synonyms: LY3298176; Dual GIP/GLP‑1 Receptor Agonist
CAS Number: 2023788‑19‑2
Sequence: Synthetic peptide analogue (proprietary modification of incretin‑based peptide structure)
Molecular Weight: Approximately 4,814.0 Da
Form: Lyophilised powder
Purity: ≥99% (HPLC)
Use: For laboratory research only. Not for human or veterinary use.
Overview
Tirzepatide is a synthetic dual‑agonist peptide designed to activate both glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors.
It is widely utilised in research examining metabolic regulation, endocrine signalling, and incretin‑mediated biological pathways under controlled laboratory conditions.
Its receptor‑targeted profile makes it suitable for in vitro and non‑human in vivo investigations involving glucose metabolism, energy balance, and peptide‑receptor interactions.
Mechanistic Insights
Preclinical and laboratory research has examined Tirzepatide in relation to several metabolic and endocrine processes:
• GIP Receptor Activation – Investigated for its role in incretin signalling and metabolic regulation pathways.
• GLP‑1 Receptor Modulation – Studied for its involvement in appetite‑related signalling and glucose‑homeostasis mechanisms in non‑human models.
• Dual‑Agonist Activity – Evaluated for coordinated receptor interactions relevant to energy‑balance and metabolic‑signalling research.
• Endocrine Pathway Investigation – Used in studies exploring hormone‑mediated feedback systems and cellular signalling networks.
These findings are derived from published scientific literature and do not imply any therapeutic or physiological effects in humans.
Research Context
Tirzepatide is utilised exclusively within controlled laboratory environments for:
• Studies involving metabolic regulation and incretin‑related pathways
• Investigations into GIP and GLP‑1 receptor signalling mechanisms
• Research on glucose homeostasis, endocrine regulation, and energy‑balance processes
• Comparative studies involving GLP‑1 analogues, GIP analogues, dual‑agonist peptides, and related receptor‑targeted compounds
This material is not intended for therapeutic, diagnostic, or clinical use.
Packaging & Storage
• Supplied as a sterile‑filtered, lyophilised peptide
• Store at –20°C, protected from light and moisture
• Reconstitute under sterile laboratory conditions using bacteriostatic water or a suitable research‑grade diluent
• Store reconstituted solutions at 2–8°C and use according to institutional guidelines
Additional solubility and technical documentation are available to qualified research institutions upon request.
Compliance Notice
This product is intended solely for laboratory research purposes.
It is not approved for human or veterinary administration and must not be incorporated into food, cosmetics, pharmaceuticals, or any product intended for biological exposure.
All information provided is for scientific and educational reference only. Researchers are responsible for ensuring compliance with all applicable regulations, institutional policies, and safety standards.
